Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06058234 · ClinicalTrials.gov registry record
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
A clinical trial of Mild Alzheimer's Disease and Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, sponsored by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group.
- Recruiting
- Registry status
- 8,680
- Enrollment target
- 1
- Study location
NCT06058234 is a study of Mild Alzheimer's Disease and Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease that is actively recruiting participants, run by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group. The registered enrollment target is 8,680 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06058234, a study of Mild Alzheimer's Disease and Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, is actively recruiting participants, sponsored by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group.
- RECRUITING
- Registry status
- 8,680 participants
- Enrollment target
- 1
- Study location
Study Summary
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Conditions Studied
Interventions
- DRUG Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Study Locations (1)
Maryland
- Centers for Medicare and Medicaid Services - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,680 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2029-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06058234
The ClinicalTrials.gov registry entry for NCT06058234 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 8,680 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Medicare and Medicaid Services/ Coverage and Analysis Group, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mild Alzheimer's Disease appearing as the primary indexed condition, and to 1 intervention - of which Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease is the first listed.
NCT06058234 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06058234 about?
NCT06058234 is a clinical study titled "Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study". The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies D...
What is the current status of trial NCT06058234?
This trial is currently recruiting. The enrollment target is 8,680 participants. The study started on 2023-07-06. Estimated completion is 2029-06-30.
What conditions does trial NCT06058234 study?
This clinical trial studies the following conditions: Mild Alzheimer's Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease.
What interventions are being tested in trial NCT06058234?
The interventions under investigation include: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (DRUG).
Who is sponsoring clinical trial NCT06058234?
This trial is sponsored by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06058234 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Mild Alzheimer's Disease
All registered trials for this condition
Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.